[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626754":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":30,"locations":31,"responsibleParty":52,"collaborators":57,"id":65,"slug":30,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":30,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":30,"overallStatus":34,"whyStopped":30,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"National Science and Technology Council, Taiwan","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Eicosapentaenoic Acid (EPA)","EXPERIMENTAL","Sample size (n=25). Four capsules of EPA will be administered at a dosage equal to two grams\u002Fday",[13],"Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Sample size (n=25). Four capsules of Placebo will be administered at a dosage equal to two grams\u002Fday",[19],"Dietary Supplement: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Eicosapentaenoic acid (omega-3 fatty acid)","25 participants are assigned",[9],[27],"Eicosapentaenoic Acid",{"type":22,"name":15,"description":24,"armGroupLabels":29,"otherNames":30},[15],null,[32],{"facility":33,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Mind Body Interface Research Center (MBI Lab & Care)","RECRUITING","Taichung","404","Taiwan","TW",{"type":40,"coordinates":41},"Point",[42,43],120.6839,24.1469,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},"Kuan-Pin Su, MD, PhD","CONTACT","+886 (04) 2205-2121","14128","cobol@cmu.edu.tw",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":56,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Kuan-Pin","Professor","Ministry of Science and Technology, Taiwan",[58,61,64],{"name":59,"class":60},"Fondation FondaMental","OTHER",{"name":62,"class":63},"Fondation pour la Recherche Médicale (FRM)","UNKNOWN",{"name":56,"class":6},"100626754",false,"NCT07439744","NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status","Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight\u002FObese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation","Inclusion Criteria:\n\n* Major depressive disorder.\n* Antidepressant drug-free.\n\nExclusion Criteria:\n\n* Schizophrenia\n* Mania\n* Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)\n* Obsessive-compulsive disorder\n* Post-traumatic stress disorder\n* Alcohol or drug abuse\u002Fdependence (except for nicotine)\n* Active suicidal ideation\n* Serious medical\u002Fneurological conditions, especially requiring corticosteroid\u002Fnon-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement","ALL","18 Years","54 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"NA","A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g\u002Fday) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \\\u003C 8%) (81), from the Taiwanese cohort. Associations with PLA2\u002FCOX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.",[82,83],"Obese Adults","MDD","2026-02-23",{"date":86,"type":87},"2026-02-27","ACTUAL",{"date":89,"type":87},"2025-03-01",{"date":91,"type":76},"2027-12",{"name":5,"class":6},1]